<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21689">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902212</url>
  </required_header>
  <id_info>
    <org_study_id>BL16</org_study_id>
    <nct_id>NCT01902212</nct_id>
  </id_info>
  <brief_title>Evaluation of an Oral Nutrition Supplement</brief_title>
  <official_title>Evaluation of an Oral Nutrition Supplement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <authority>France: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to capture gastrointestinal tolerance (GI) information on a
      nutrient dense oral nutritional supplement (ONS) in healthy elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Gastro-Intestinal Tolerance</measure>
    <time_frame>Study Day (SD) 1-8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ONS Consumption</measure>
    <time_frame>SD 1-8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Consumption Record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Screening and SD 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastrointestinal Tolerance</condition>
  <arm_group>
    <arm_group_label>Oral Nutritional Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 servings a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Nutritional Supplement</intervention_name>
    <arm_group_label>Oral Nutritional Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible for the study if they meet all of the following inclusion
        criteria:

          -  Male or female ≥ 60 and ≤ 90 years of age.

          -  Body Mass Index (BMI) &gt; 20 but &lt; 35.

        Exclusion Criteria:

        Subjects will be excluded from the study if they meet any of the following criteria:

          -  History of diabetes

          -  Antibiotic use within 1 week prior to enrollment

          -  Undergone major surgery less than 3 months prior to enrollment.

          -  Current active malignant disease or was treated within the last 6 months for cancer.

          -  Immunodeficiency disorder.

          -  Myocardial infarction within the last 3 months.

          -  Chronic obstructive pulmonary disease (COPD).

          -  Allergy to any of the ingredients in the study product.

          -  Obstruction of the gastrointestinal tract or other major gastrointestinal disease.

          -  Dementia, brain metastases, eating disorders, history of significant neurological or
             psychiatric disorder.

          -  Unintentional weight loss or weight gain ≥ 5% in last 4 weeks.

          -  Taking medications/dietary supplements/substances that could profoundly modulate
             metabolism or affect GI motility.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Nelson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen DeLuca, MS, RD, LD</last_name>
    <phone>614-624-5455</phone>
    <email>kristen.deluca@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bobbie Swearengin, RN</last_name>
    <phone>614-624-7182</phone>
    <email>bobbie.swearengin@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biofortis Sas</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Gendre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 16, 2013</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
